Stocks scoring 25–45 beat the S&P 500
45.3% of the time over the next three months, since 2015.
How we measured this →
8
hedge funds
hold it · 1 new, 3 added, 2 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$3.6B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About XENON PHARMACEUTICALS INC
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending…
Who's behind the signal
Every informed buyer we can see on XENE, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
XENON PHARMACEUTICALS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
3
Increasing
2
Decreasing
2
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to XENON PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell XENON PHARMACEUTICALS INC or any security.